<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005110'>Atrial fibrillation</z:hpo> is the most common clinically relevant heart rhythm disorder and is associated with increased morbidity and mortality </plain></SENT>
<SENT sid="1" pm="."><plain>Most important risk factors for <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> are high age, arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, <z:hpo ids='HP_0001635'>heart failure</z:hpo> and <z:e sem="disease" ids="C0035439" disease_type="Disease or Syndrome" abbrv="rhd">rheumatic heart disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> is classified as paroxysmal, persistent, long-standing persistent and <z:hpo ids='HP_0004754'>permanent atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Spontaneous conversion to sinus rhythm is observed in <z:hpo ids='HP_0004757'>paroxysmal atrial fibrillation</z:hpo>, whereas in persistent <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo>, pharmacological or electrical cardioversion is required in order to restore sinus rhythm </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:hpo ids='HP_0004754'>permanent atrial fibrillation</z:hpo>, the arrythmia is accepted by patient and physician and cardioversion is not attempted </plain></SENT>
<SENT sid="5" pm="."><plain>Rate control only is thus applied in <z:hpo ids='HP_0004754'>permanent atrial fibrillation</z:hpo>, whereas in paroxysmal and persistent <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo>, addition rhythm control with anti-arrhythmic drugs and/or ablation is attempted if symptoms persist and age and co-morbidities do not pose contra-indications </plain></SENT>
<SENT sid="6" pm="."><plain>Besides rhythm management, oral anticoagulation is the mainstay of therapy for most patients with <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Risk scores such as the CHA2DS2-VASc score help to identify patients with a high risk of <z:hpo ids='HP_0001297'>stroke</z:hpo> and need for oral anticoagulation </plain></SENT>
<SENT sid="8" pm="."><plain>The underuse of <z:chebi fb="6" ids="28384">vitamin K</z:chebi> <z:chebi fb="68" ids="48706">antagonists</z:chebi> in clinical practise is partly due to considerable disadvantages: an increased <z:mp ids='MP_0001914'>bleeding</z:mp> risk, a narrow therapeutic window and multiple drug interactions prompting frequent laboratory controls to assess an individual dosage </plain></SENT>
<SENT sid="9" pm="."><plain>New oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> targeting thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban and edoxaban) may replace <z:chebi fb="8" ids="10033">warfarin</z:chebi> in many patients with <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> due to convincing data both on efficacy and safety as well as convenience </plain></SENT>
<SENT sid="10" pm="."><plain>However, challenges remain with respect to lack of specific <z:chebi fb="183" ids="50247">antidotes</z:chebi> and high costs </plain></SENT>
</text></document>